Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

Chest

Volumn 108, Issue 4 SUPPL., 1995, Pages 258S-275S

  Hirsh, J ^a   Raschke, R ^a   Warkentin, T E ^a   Dalen, J E ^a   Deykin, D ^a   Poller, L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANCROD; ANTITHROMBOCYTIC AGENT; DANAPAROID; HEPARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MOLECULAR WEIGHT; OSTEOPOROSIS; PRIORITY JOURNAL; SKIN NECROSIS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0028785452     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.108.4_Supplement.258S     Document Type: Conference Paper

References (271)

1. Choay J Petitou M. The chemistry of heparin: a way to understand its mode of action Med J Aust 144 1986 7 10
2. Rosenberg RD Lam L. Correlation between structure and function of heparin Proc Natl Acad Sci USA 76 1979 1218 1222
3. Rosenberg RD Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism Colman RW Hirsh J Marder VJ Hemostasis and thrombosis: basic principles and clinical practice 3rd ed. 1992 JB Lippincott Philadelphia 837 860
4. Lindahl U Backstrom G Hook M Structure of the antithrombin-binding site of heparin Proc Natl Acad Sci USA 76 1979 3198 3202
5. Hook M Bjork I Hopwood J Anticoagulant activity of heparin: separation of high activity and low-activity heparin species by affinity chromatography on immobilized antithrombin FEBS Lett 66 1976 90 93
6. Casu B Oreste P Torri G The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin Ill-binding sequence Biochem J 197 1981 599 609
7. Ellis V Scully MF Kakkar VV. The relative molecular mass dependence of the antifactor Xa properties of heparin Biochem J 238 1986 329 333
8. Choay J Lormeau JC Petitou M Structural studies on a biologically active hexasaccharide obtained from heparin Ann NY Acad Sci 370 1981 644 649
9. Choay J Petitou M Lormeau JC Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity Biochem Biophys Res Commun 116 1983 492 499
10. Lindahl U Thunberg L Backstrom G Extension and structural variability of the antithrombin-binding sequence in heparin J Biol Chem 259 1984 12368 12376
11. Atha DH Lormeau JC Petitous M Contribution of 3–0- and 6–0-sulfated blycosamine residues in the heparin-induced conformational change in antithrombin III Biochemistry 26 1987 6454 6461
12. Oosta GM Gardner WT Beeler DL Multiple functional domains of the heparin molecule Proc Natl Acad Sci USA 78 1981 829 833
13. Petitou M. Synthetic heparin fragments: new and efficient tools for the study of heparin and its interactions Nouv Rev Fr Hematol 26 1984 221 226
14. Rosenberg RD Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor J Biol Chem 248 1973 6490 6506
15. Rosenberg RD Jordon RE Favreau LV High active heparin species with multiple binding sites for antithrombin Biochem Biophys Res Commun 86 1979 1319 1324
16. Thunberg L Backstrom G Lindahl U. Further characterization of antithrombin-binding sequence in heparin Carbohydr Res 100 1982 393 410
17. Bjork I Lindahl U. Mechanism of the anticoagulant action of heparin Mol Cell Biochem 48 1982 161 182
18. Nordenman B Bjork I. Binding of low affinity and high affinity heparin to antithrombin: ultraviolet difference spectroscopy and circular dichroism studies Biochemistry 17 1978 3339 3344
19. Olson ST Srinivasan KR Bjork I Binding of high affinity heparin to antithrombin III: stopped flow kinetic studies of the binding interaction J Biol Chem 256 1981 11073 11079
20. Villanueva GB Danishefsky I. Evidence for a heparin-induced conformational change on antithrombin III Biochem Biophys Res Commun 74 1977 803 809
21. Ofosu FA Modi GJ Hirsh J Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides Ann NY Acad Sci 485 1986 41 55
22. Ofosu FA Esmon CT Blajchman MA Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa Biochem J 257 1989 143 150
23. Beguin S Mardiguian J Lindhout T The mode of action of low molecular weight heparin preparation (PK 10169) and two of its major components on thrombin generation in plasma Thromb Haemost 61 1989 30 34
24. Hemker HC. The mode of action of heparin in plasma Verstraete M Vermylen J Lijnen HR Eleventh congress on thrombosis and haemostasis 1987 Leuven University Press Brussels 17 36
25. Beguin S Lindhout T Hemker HC. The mode of action of heparin in plasma Thromb Haemost 60 1989 457 462
26. Olson ST Shore JD. Demonstration of a two-step reaction mechanism for inhibition of α-thrombin by antithrombin III and identification of the step affected by heparin J Biol Chem 257 1982 14891 14895
27. Danielsson A Raub E Lindahl U Role of ternary complexes in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa J Biol Chem 261 1986 15467 15473
28. Holmer E Lindahl U Backstrom G Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin Thromb Res 18 1980 861 869
29. Jordan RE Oosta GM Gardner WT The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin J Biol Chem 255 1980 10081 10090
30. Lane DA Denton J Flynn AM Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4 Biochem J 218 1984 725 732
31. Tollefsen DM Majerus DW Blank MK. Heparin cofactor II: purification and properties of thrombin in human plasma J Biol Chem 257 1982 2162 2169
32. Maimone MM Tollefsen DM. Activation of heparin cofactor II by heparin oligosaccharides Biochem Biophys Res Commun 152 1988 1056 1061
33. Hurst RE Poon MC Griffith MJ. Structure-activity relationships of heparin: independence of heparin charge density and antithrombin binding domains in thrombin inhibition by antithrombin and heparin cofactor II J Clin Invest 72 1983 1042 1045
34. Petitou M Lormeau JC Perly B Is there a unique sequence in heparin for interaction with heparin cofactor II?: structural and biological studies of heparin-derived oligosaccharides J Biol Chem 263 1988 8685 8690
35. Sie P Petitou M Lormeau JC Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II Biochem Biophys Acta 966 1988 188 195
36. Andersson L-O Barrowcliffe TW Holmer E Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X: effect of heparin neutralization in plasma Thromb Res 15 1979 531 541
37. Harenberg J. Pharmacology of low molecular weight heparins Semin Thromb Hemost 16 1990 12 18
38. Johnson EA Mulloy B. The molecular weight range of commercial heparin preparations Carbohydr Res 51 1976 119 127
39. Brill-Edwards P Ginsberg JS Johnston M Establishing a therapeutic range for heparin therapy Ann Intern Med 119 1993 104 109
40. Hirsh J. Heparin N Engl J Med 324 1991 1565 1574
41. Pini M Pattachini C Quintavalla R Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis: a randomized clinical trial Thromb Haemost 64 1990 222 226
42. Hommes DW Bura A Mazzolai L Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis: a meta-analysis Ann Intern Med 116 1992 279 284
43. Hull RD Raskob GE Hirsh J Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis N Engl J Med 315 1986 1109 1114
44. Lane DA Pejler G Flynn AM Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4 J Biol Chem 261 1986 3980 3986
45. Lijnen HR Hoylaerts M Collen D. Heparin binding properties of human histidine-rich glycoprotein: mechanism and role in the neutralization of heparin in plasma J Biol Chem 258 1983 3803 3808
46. Peterson CB Morgan WT Blackburn MN Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin J Biol Chem 262 1987 7567 7574
47. Holt JC Niewiarowski S. Biochemistry of a-granule proteins Semin Hematol 22 1985 151 163
48. Preissner KT Muller-Berghaus G. Neutralization and binding of heparin by S-protein/vitroneetin in the inhibition of factor Xa by antithrombin III J Biol Chem 262 1987 12247 12253
49. Dawes J Pavuk N. Sequestration of therapeutic glycosaminoglycans by plasma fibronectin [abstract] Thromb Haemost 65 1991 829
50. Sobel M McNeill PM Carlson PL Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo J Clin Invest 87 1991 1787 1793
51. Hirsh J van Aken WG Gallus AS Heparin kinetics in venous thrombosis and pulmonary embolism Circulation 53 1976 691 695
52. Young E Prins MH Levine MN Heparin binding to plasma proteins, an important mechanism for heparin resistance Thromb Haemost 67 1992 639 643
53. Barzu T Molho P Tobelem G Binding and endocytosis of heparin by human endothelial cells in culture Biochem Biophys Acta 845 1985 196 203
54. De Swart CAM Nijmeyer B Roelofs JMM Kinetics of intravenously administered heparin in normal humans Blood 60 1982 1251 1258
55. Olsson P Lagergren H Ek S. The elimination from plasma of intravenous heparin: an experimental study on dogs and humans Acta Med Scand 173 1963 619 630
56. Bjornsson TO Wolfram BS Kitchell BB. Heparin kinetics determined by three assay methods Clin Pharmacol Ther 31 1982 104 113
57. Glimelius B Busch C Hook M. Binding of heparin on the surface of cultured human endothelial cells Thromb Res 12 1978 773 782
58. Mahadoo J Hiebert L Jaques LB. Vascular sequestration of heparin Thromb Res 12 1977 79 90
59. Friedman Y Arsenis C. Studies on the heparin sulphamidase activity from rat spleen: intracellular distribution and characterization of the enzyme Biochem J 139 1974 699 708
60. Dawes J Pepper DS. Catabolism of low-dose heparin in man Thromb Res 14 1979 845 860
61. McAllister BM Demis DJ. Heparin metabolism: isolation and characterization of uroheparin Nature 212 1966 293 294
62. Bara L Billaud E Gramond G Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration Thromb Res 39 1985 631 636
63. Turpie AGG Robinson JG Doyle DJ Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction N Engl J Med 320 1989 352 394
64. Cruickshank MK Levine MN Hirsh J A standard heparin nomogram for the management of heparin therapy Arch Intern Med 151 1991 333 337
65. Camilleri JF Bonnet JL Bouvier JL Thrombolyse intraveineuse dans l'infarctus du myocarde: influence de la qualite de l'antiocoagulation sur le taux de recidives precoces d'angor ou d'infarctus Arch Mal Coeur 81 1988 1037 1041
66. Kaplan K Davison R Parker M Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction Am J Cardiol 59 1987 241 244
67. De Bono DP Simoons ML Tijssen J Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group Trial Br Heart J 67 1992 122 128
68. Young E Wells P Holloway S Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin Thromb Haemost 71 1994 300 304
69. Levine M Hirsh J Gent M A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin Arch Intern Med 154 1994 49 56
70. Chiu HM Hirsh J Yung WL Relationship between anticoagulant and antithrombotic effects of heparin Blood 49 1987 171 184
71. Stevenson KJ Easton AC Curry A The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure Thromb Haemost 55 1986 250 258
72. D'Angelo A Seveso MP D'Angelo SV Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT): implications in heparin monitoring by APTT Am J Clin Pathol 94 1990 297 306
73. Shojania AM Tetreault J Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer Am J Clin Pathol 89 1988 19 23
74. Brandjes DPM Heijboer H Buller HR Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis N Engl J Med 327 1992 1485 1489
75. Raschke RA Reilly BM Guidry JR The weight-based heparin dosing nomogram compared with a ‘standard care’ nomogram Ann Intern Med 119 1993 874 881
76. Hull RD Raskob GE Rosenbloom D Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis N Engl J Med 322 1990 1260 1264
77. Prandoni P Lensing AWA Buller HR Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis Lancet 339 1992 441 445
78. Simmoneau G Charbonnier B Decousus H Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis Arch Intern Med 153 1993 1541 1546
79. Basu D Gallus A Hirsh J A prospective study of value of monitoring heparin treatment with the activated partial thromboplastin time N Engl J Med 287 1972 324 327
80. Morabia A. Heparin doses and major bleedings Lancet 1 1986 1278 1279
81. Fennerty AG Thomas P Backhouse G Audit of control of heparin treatment BMJ 290 1985 27 28
82. Reilly B Raschke R Sandhya S Intravenous heparin dosing: patterns and variations in internist's practices J Gen Intern Med 8 1993 536 542
83. Wheeler AP Jaquiss RD Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis Arch Intern Med 148 1988 1321 1325
84. LeBras P Halfon P. Standardization of heparin therapy improves efficacy [letter] Arch Intern Med 152 1992 2140 2143
85. Hull RD Raskob GE Rosenbloom D Optimal therapeutic level of heparin therapy in patients with venous thrombosis Arch Intern Med 152 1992 1589 1595
86. Elliot GC Hiltunen SJ Suchyta M Physician-guided treatment compared with a heparin protocol for deep vein thrombosis Arch Intern Med 154 1994 999 1004
87. Flaker GC Bartolozzi J Davis V Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction Arch Intern Med 154 1994 1492 1496
88. Mungall DR Anbe D Forrester PL A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram-directed heparin therapy Clin Pharmacol Ther 55 1994 591 596
89. Kershaw B White RH Mungall DM Computer-assisted dosing of heparin Arch Intern Med 154 1994 1005 1011
90. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-82
91. Braunwald E, Mark DB, Jones RH, et al. US Dept of Health and Human Services, Clinical Practice Guidelines. Unstable angina: diagnosis and management. AHCPR publication No. 94–0602, 1994; 63–4
92. Raschke RA Reilly B. Monitoring heparin therapy [letter] Ann Intern Med 120 1994 169 170
93. College of American Pathologists. 1994 CAP surveys, set CG2-A. Northfield, 111: College of American Pathologists, 1994; 5–9
94. Raschke RA Hertel G. Clinical use of the heparin nomogram [letter] Arch Intern Med 151 1991 2318 2321
95. Levine MN. Clinical use of the heparin nomogram [reply] Arch Intern Med 151 1991 2321
96. Venous Thrombosis Clinical Study Group. Small doses of subcutaneous sodium heparin in the prevention of deep vein thrombosis after elective hip operations. Br J Surg 1975; 62:348-50
97. Gallus AS Hirsh J Tuttle RJ Small subcutaneous doses of heparin in prevention of venous thrombosis N Engl J Med 288 1973 545 551
98. Sagar S Naim D Stamatakis JD Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement Lancet 1 1976 1151 1154
99. Moskovitz PA Ellenberg SS Feffer HL Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures J Bone Joint Surg Am 60 1978 1065 1070
100. Poller L Tabemer DA Sandilands DG An evaluation of APTT monitoring of low-dose heparin dosage in hip surgery Thromb Haemost 47 1982 50 53
101. Leyvraz PF Richard J Bachmann F Adjusted versus fixed dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement N Engl J Med 309 1983 954 958
102. Tabemer DA Poller L Thomson JM Randomized study of adjusted versus fixed low dose heparin prophylaxis of deep vein thrombosis in hip surgery Br J Surg 76 1989 933 935
103. Christopher B, for the GUSTO I investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO I trial. Circulation (in press)
104. GUSTO IIa Investigators. Global use of strategies to open coronary arteries (GUSTO) IIa Investigators: randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90:1631-37
105. Antmann EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90:1624-30
106. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
107. Levine M. Nonhemorrhagic complications of anticoagulant therapy Semin Thromb Hemost 12 1986 63 66
108. Howell R Fidler J Letsky E The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial Br J Obstet Gynaecol 90 1983 1124 1128
109. Monreal M Lafoz E Olive A Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (fragmin) in patients with venous thromboembolism and contraindications to coumarin Thromb Haemost 71 1994 7 11
110. Griffith CC Nichols G Asher JD Heparin osteoporosis JAMA 193 1965 85 88
111. Jaffe MD Willis PW. Multiple fractures associated with longterm sodium heparin therapy JAMA 193 1965 152 154
112. Buchwald H Rhode TD Schneider PD Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis Surgery 88 1980 507 516
113. Rupp WM McCarthy HB Rohde TD Risk of osteoporosis in patients treated with long-term intravenous heparin Curr Surg 39 1982 419 422
114. Sackler JP Liu L. Heparin-induced osteoporosis Br J Radiol 46 1973 548 550
115. Miller WE DeWolfe VG. Osteoporosis resulting from heparin therapy Cleve Clin Q 33 1966 31 34
116. Aarskog D Aksnes L Lehmann L. Low 1,23-dihydroxyvitamen D in heparin-induced osteopenia Lancet 2 1980 650 651
117. Griffiths HT Liu DTY. Severe heparin osteoporosis in pregnancy Postgrad Med 60 1984 424 425
118. Hellgren M Nygards CB. Long-term therapy with subcutaneous heparin during pregnancy Gynecol Obstet Invest 13 1982 76 89
119. Megard M Cuche M Grapeloux A Osteoporose de l'heparinotherapie analyse histonophometrique de la biopsie osseuse Nouv Presse Med 11 1982 261 264
120. Squires JW Pinch LWC. Heparin-induced spinal fractures JAMA 241 1979 2417 2418
121. Wise PH Hall AJ. Heparin-induced osteopenia in pregnancy BMJ 281 1980 110 111
122. Dahlman T Lindvall N Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study postpartum Br J Obstet Gynaecol 97 1990 221 228
123. Ginsberg JS Kowalchuk G Hirsh J Heparin effect on bone density Thromb Haemost 64 1990 286 289
124. Ambrus JL Robin JC Kelly RS Studies on osteoporosis: I. Experimental models: effect of age, sex, genetic background, diet, steroid and heparin treatment on calcium metabolism of mice Res Commun Chem Pathol Pharmacol 22 1978 3 14
125. Avioli LV. Heparin induced osteoporosis: an appraisal Adv Exp Med Biol 52 1975 375 387
126. Hull RD Delmore T Carter C Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis N Engl J Med 306 1982 189 194
127. Nelson JC Lerner RG Goldstein R Heparin-induced thrombocytopenia Arch Intern Med 138 1978 548 552
128. Chong BH Ismail F. The mechanism of heparin-induced platelet aggregation Eur J Haematol 43 1989 245 251
129. Chong BH Pitney WR Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation Lancet 2 1982 1246 1249
130. Warkentin TE Levine MN Hirsh J Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1995 1330 1335
131. Ansell J Slepchuk N Jr Kumar R Heparin induced thrombocytopenia: a prospective study Thromb Haemost 43 1980 61 65
132. Ansell JE Price JM Shah S Heparin-induced thrombocytopenia: what is its real frequency? Chest 88 1985 878 882
133. Bailey RT Ursick JA Heim KL Heparin-associated thrombocytopenia: a prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin Drug Intell Clin Pharmacol 20 1986 374 378
134. Ramirez-Lassepas M Cipolle RJ Rodvold KA Heparin-induced thrombocytopenia in patients with cerebrovascular disease Neurology 34 1984 736 740
135. Cipolle RJ Rodvold KA Seifert R Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients Ther Drug Monit 5 1983 205 211
136. Gallus AS Goodall KT Beswick W Heparin-associated thrombocytopenia: case report and prospective study Aust NZ J Med 10 1980 25 31
137. Green D Martin GJ Shoichet SH Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin Am J Med Sci 288 1984 60 64
138. Green D. Heparin-induced thrombocytopenia Med J Aust 144 suppl 1986 HS37 9
139. Powers PJ Cuthbert D Hirsh J. Thrombocytopenia found uncommonly during heparin therapy JAMA 241 1979 2396 2397
140. Powers PJ Kelton JG Carter CJ. Studies on the frequency of heparin-associated thrombocytopenia Thromb Res 33 1984 439 443
141. Rao AK White GC Sherman L Low incidence of thrombocytopenia with porcine mucosal heparin: a prospective study Arch Intern Med 149 1989 1285 1288
142. King DJ Kelton JG. Heparin-associated thrombocytopenia Ann Intern Med 100 1984 535 540
143. Warkentin TE Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia Bounameaux H Goldhaber SZ Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases: fundamental and clinical cardiology 1994 Marcel Dekker New York 75 127 ed-in-chief)
144. Kapsch DN Adelstein EH Rhodes GR Heparin-induced thrombocytopenia, thrombosis and hemorrhage Surgery 86 1979 148 155
145. White PW Sadd JR Nensel RE. Thrombotic complications of heparin therapy, including six cases of heparin-induced skin necrosis Ann Surg 190 1979 595 608
146. Warkentin TE Kelton JG. Heparin-induced thrombocytopenia: predominance of venous thrombotic complications, and a high risk for subsequent thrombosis in patients who are initially recognized with isolated thrombocytopenia [abstract 738] Blood 84 suppl 1 1994 188 A
147. Towne JB Bernhard VM Hussey C White clot syndrome: peripheral vascular complications of heparin therapy Arch Surg 114 1979 372 377
148. Battey PM Salam AA. Venous gangrene associated with heparin-induced thrombocytopenia Surgery 97 1985 618 620
149. Cohen DJ Briggs R Head HD Phlegmasia cerulea dolens and its association with hypercoagulable states: case reports Angiology 40 1989 498 508
150. Calhoun BC Hesser JW. Heparin-associated antibody with pregnancy: discussion of two cases Am J Obstet Gynecol 156 1987 964 966
151. Kyritsis AP Williams EC Schutta HS. Cerebral venous thrombosis due to heparin-induced thrombocytopenia Stroke 21 1990 1503 1505
152. Meagher AP Lord RSA Graham AR Acute aortic occlusion presenting with lower limb paralysis J Cardiovasc Surg 32 1991 643 647
153. Stanton PE Jr Evans JR Lefemine AA White clot syndrome South Med J 81 1988 616 620
154. Sobel M Adelman B Szentpetery S Surgical management of heparin-associated thrombocytopenia: strategies in the treatment of venous and arterial thromboembolism J Vasc Surg 8 1988 395 401
155. Cimo PL Moake JL Weinger RS Heparin-induced thrombocytopenia: association with a platelet-aggregating factor and arterial thromboses Am J Hematol 6 1979 125 133
156. Dion D Dumesnil JG LeBlanc P. In situ right ventricular thrombus secondary to heparin induced thrombocytopenia Can J Cardiol 5 1989 308 310
157. Hall AV Clark WF Parbtani A. Heparin-induced thrombocytopenia in renal failure Clin Nephrol 38 1992 86 89
158. Bemasconi F Metivet F Estrade G Thrombose d'une prosthèse valvulaire mitrale au cours d'une thrombopénie induite par l'héparine: traitement fibrinolytique Presse Med 17 1988 1366
159. Arthur CK Grant SJB Murray WK Heparin-associated acute adrenal insufficiency Aust NZ J Med 15 1985 454 455
160. Ernest D Fisher MM. Heparin-induced thrombocytopaenia complicated by bilateral adrenal haemorrhage Intensive Care Med 17 1991 238 240
161. Findling JW Korducki JM Lahiri PK Bilateral adrenal hemorrhage associated with heparin-induced thrombocytopenia Wis Med J 86 1987 27 29
162. Souid F Pourria JL Le Roux G Adrenal haemorrhagic necrosis related to heparin-associated thrombocytopenia Crit Care Med 19 1991 297 299
163. Warkentin TE Soutar RL Panju A Acute systemic reactions to intravenous bolus heparin therapy: characterization and relationship to heparin-induced thrombocytopenia [abstract] Blood 80 suppl 1 1992 160 a
164. Warkentin TE Hirte HW Anderson DR Transient global amnesia associated with acute heparin-induced thrombocytopenia Am J Med 97 1994 489 491
165. Tuneu A Moreno A de Moragas JM. Cutaneous reactions secondary to heparin injections J Am Acad Dermatol 12 1985 1072 1077
166. Platell CFE Tan EGC. Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions Aust NZ J Surg 56 1986 621 623
167. Stricker H Lämmle B Furlan M Heparin-dependent in vitro aggregation of normal platelets by plasma of a patient with heparin-induced skin necrosis: specific diagnosis for a rare side effect Am J Med 85 1988 721 724
168. Fowlie J Stanton PD Anderson JR. Heparin-associated skin necrosis Postgrad Med J 66 1990 573 575
169. Hach-Wunderle V Kainer K Krug B Heparin-associated thrombosis despite normal platelet counts [letter] Lancet 344 1994 469 470
170. Kelton JG Sheridan D Santos A Heparin-associated thrombocytopenia: laboratory studies Blood 72 1988 925 930
171. Chong BH Fawaz I Chesterman CN Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets Br J Haematol 73 1989 235 240
172. Amiral J Bridey F Dreyfus M Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter] Thromb Haemost 68 1992 95 96
173. Kelton JG Smith JW Warkentin TE Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4 Blood 83 1994 3232 3239
174. Visentin GP Ford SE Scott JP Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells J Clin Invest 93 1994 81 88
175. Greinacher A Pötzsch B Amiral J Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen Thromb Haemost 71 1994 247 251
176. Chong BH Murray B Berndt MC Plasma P-selectin is increased in thrombotic consumptive platelet disorders Blood 83 1994 1535 1541
177. Warkentin TE Hayward CPM Boshkov LK Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia Blood 84 1994 3691 3699
178. Cines DB Tomaski A Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia N Engl J Med 316 1987 581 589
179. Sheridan D Carter C Kelton JG. A diagnostic test for heparin-induced thrombocytopenia Blood 67 1986 27 30
180. Greinacher A Michels I Kiefel V A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia Thromb Haemost 66 1991 734 736
181. Warkentin TE Hayward CPM Smith CA Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia J Lab Clin Med 120 1992 371 379
182. Chong BH Burgess J Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia Thromb Haemost 69 1993 344 350
183. Favaloro EJ Bernal-Hoyos E Exner T Heparin-induced thrombocytopenia: laboratory investigation and confirmation of diagnosis Pathology 24 1992 177 183
184. Kelton JG Sheridan D Brain M Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia J Lab Clin Med 103 1984 606 612
185. Greinacher A Amiral J Dummel V Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay Transfusion 34 1994 381 385
186. Greinacher A Michels I Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific Thromb Haemost 67 1992 545 549
187. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172) Thromb Haemost 70 1993 554 561
188. Benhamou AC Gruel Y Barsotti J The white clot syndrome or heparin-associated thrombocytopenia and thrombosis (WCS or HATT): (26 cases) Int Angiol 4 1985 303 310
189. Reuter HD. Niedermolekulares heparin in der therapie der heparininduzierten thrombozytopenie Med Klin 82 1987 115 118
190. Gouault-Heilmann M Payen D Contant G Thrombocytopenia related to synthetic heparin analogue therapy [letter] Thromb Haemost 54 1985 557
191. Follea G Hamandjian I Trzeciak MC Pentosan polysulphate associated thrombocytopenia Thromb Res 42 1986 413 418
192. Horellou MH Conard J Lecrubier C Persistent heparin-induced thrombocytopenia despite therapy with low molecular weight heparin Thromb Haemost 13 1987 126 130
193. Vitoux JF Mathieu JF Roncato M Heparin-associated thrombocytopenia: treatment with low molecular weight heparin Thromb Haemost 55 1986 37 46
194. Copplestone A Oscier DG. Heparin-induced thrombocytopenia in pregnancy [letter] Br J Haematol 65 1987 248
195. Demers C Ginsberg JS Brill-Edwards P Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia Blood 78 1991 2194 2197
196. Cole CW Bormanis J. Ancrod: a practical alternative to heparin J Vasc Surg 8 1988 59 63
197. Greinacher A Liebenhoff U Kiefel V Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation—a possible new indication for high-dose IV IgG Thromb Haemost 71 1994 641 645
198. Krishnamurti C Bolan CD Reid TJ III Pharmacology and mechanism of action of ancrod: potential for inducing thrombosis [letter] Blood 79 1992 2492
199. Levine LE Bernstein JE Soltani K Heparin-induced cutaneous necrosis unrelated to injection sites: a sign of potentially lethal complications Arch Dermatol 119 1983 400 403
200. Kelly RA Gelfand JA Pincus SH. Cutaneous necrosis caused by systemically administered heparin JAMA 246 1981 1582 1583
201. Rongioletti F Pisani S Ciaccio M Skin necrosis due to intravenous heparin Dermatologica 178 1989 47 50
202. Abbott EC Gornal AC Sutherland DJA The influence of a heparin-like compound on hypertension electrolytes and aldosterone in man Can Med Assoc J 94 1966 1155 1164
203. Conn JW Rovner DR Cohen EL Inhibition of heparinoid on aldosterone biosynthesis in man J Clin Endocrinol Metab 26 1966 527 532
204. Lechey D Gantt C Lim V. Heparin-induced hypoaldosteronism JAMA 246 1981 2189 2190
205. Phelps KR Oh MS Carrol HJ. Heparin-induced hyperkalemia: report of a case Nephron 25 1980 254 258
206. Wilson ID Goetz FC. Selective hypoaldosteronism after prolonged heparin administration Am J Med 36 1964 635 640
207. Klein LA Hall RL Smith RB. Surgical treatment of priapism: with a note on heparin-induced priapism J Urol 108 1972 104 106
208. Duggan ML Morgan C Jr. Heparin: a cause of priapism? South Med J 63 1970 1131 1134
209. Andriuoli G Mastacchi R Barnti M Comparison of the antithrombotic and hemorrhagic effects of heparin and a new low molecular weight heparin in the rat Haemostasis 15 1985 324 330
210. Bergqvist D Nilsson B Hedner U The effects of heparin fragments of different molecular weight in experimental thrombosis and haemostasis Thromb Res 38 1985 589 601
211. Cade JF Buchanan MR Boneu B A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation Thromb Res 35 1984 613 625
212. Carter CJ Kelton JG Hirsh J The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin Blood 59 1982 1239 1245
213. Esquivel CO Bergqvist D Bjork C-G Comparison between commercial heparin, low-molecular weight heparin and pentosan polysulphate on haemostasis and platelets in vivo Thromb Res 28 1982 389
214. Holmer E Matsson C Nilsson S. Anticoagulant and antithrombotic effects of low molecular weight heparin fragments in rabbits Thromb Res 25 1982 475 485
215. Anderson DR O'Brien BJ Levine MN Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty Ann Intern Med 119 1993 1105 1112
216. Hull R Raskob G Pineo G A comparison of subcutaneous low-molecular-weight heparin with sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation N Engl J Med 19 1993 1370 1375
217. Hull RD Raskob GE Pineo GF Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis N Engl J Med 326 1992 975 982
218. Lensing AWA Prins MH Davidson BL Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis Arch Intern Med 155 1994 601 607
219. Ofosu FA Barrowcliffe TW. Mechanisms of action of low molecular weight heparins and heparinoids Hirsh J Antithrombotic therapy, Bailliere's clinical haematology, (vol 3) 1990 Bailliere Tindall London 505 529
220. Jordan RE Favreau LV Braswell EH Heparin with two binding sites for antithrombin or platelet factor 4 J Biol Chem 257 1982 400 406
221. Lane DA. Heparin binding and neutralizing protein Lane DA Lindahl U Heparin, chemical and biological properties: clinical applications 1989 Edward Arnold London 363 374
222. Salzman EW Rosenberg RD Smith MH Effect of heparin and heparin fractions on platelet aggregation J Clin Invest 65 1980 64 73
223. Holmer E Kurachi K Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor IXa, factor XIIa and kallikrein by antithrombin Biochem J 193 1981 395 400
224. Holmer E Soderberg K Bergqvist D Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties Haemostasis 16 suppl 2 1986 1 7
225. Handeland GF Abidgaard GF Holm U Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin Eur J Clin Pharmacol 39 1990 107 112
226. Ockelford PA Carter CJ Mitchell L Discordance between the anti-Xa activity and antithrombotic activity of an ultra-low molecular weight heparin fraction Thromb Res 28 1982 401 409
227. Barzu T Molho P Tobelem G Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture Nouv Rev Fr Haematol 26 1984 243 247
228. Barzu T Van Rijn JLMC Petitou M Heparin degradation in the endothelial cells Thromb Res 47 1987 601 609
229. Boneu B Caranobe C Cadroy Y Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit Semin Thromb Hemost 14 1988 18 27
230. Bradbrook ID Magnani HN Moelker HC ORG 10172: a low molecular weight heparinoid anticoagulant with a long half life in man Br J Clin Pharmacol 23 1987 667 675
231. Bratt G Tornebohm E Widlund L Low molecular weight heparin (KABI 2165, FRAGMIN): pharmacokinetics after intravenous and subcutaneous administration in human volunteers Thromb Res 42 1986 613 620
232. Briant L Caranobe C Saivin S Unfractionated heparin and CY216: pharmacokinetics and bioavailabilities of the anti-factor Xa and IIa. Effects of intravenous and subcutaneous injection in rabbits Thromb Haemost 61 1989 348 353
233. Frydman A Bara L Leroux Y The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80 mg J Clin Pharmacol 28 1988 608 618
234. Matzsch T Bergqvist D Hedner U Effect of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers Thromb Haemost 57 1987 97 101
235. Stiekema JC Wijnand HP Van Dinther TG Safety and pharmacokinetics of the low molecular weight heparinoid ORG 10172 administered to healthy elderly volunteers Br J Clin Pharmacol 27 1989 39 48
236. Caranobe C Barret A Gabaig AM Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of low molecular weight heparin (CY216) in normal and nephrectomized rabbits Thromb Res 40 1985 129 133
237. Palm M Mattsson CH. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance Thromb Haemost 58 1987 932 935
238. Boneu B Buchanan MR Cade JF Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo Thromb Res 40 1985 81 89
239. Henny CP ten Cate H ten Cate JW A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs J Lab Clin Med 106 1985 187 196
240. Hobbelen PM Vogel GM Meuleman DG. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid ORG 10172 or heparin to rats Thromb Res 48 1987 549 558
241. Van Ryn-McKenna J Gray E Weber E Effects of sulphated polysaccharides on inhibition of thrombus formation initiated by different stimuli Thromb Haemost 61 1989 7 9
242. Van Ryn-McKenna J Ofosu FA Hirsh J Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulfation Br J Haematol 71 1989 265 269
243. Fabris F Fussi F Casonato A Normal and low molecular weight heparins: interaction with human platelets Eur J Clin Invest 13 1983 135 139
244. Fernandez F Nguyen P Van Ryn J Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect Thromb Res 43 1986 491 495
245. Blajchman MA Young E Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight on vessel wall permeability in rabbits Ann NY Acad Sci 556 1989 245 254
246. Levine MN Hirsh J Gent M Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin Ann Intern Med 114 1991 545 551
247. Hull RD Raskob GE Pineo GF A randomized double-blind trial of low molecular weight heparin in the initial treatment of proximal vein thrombosis [abstract] Thromb Haemost 65 suppl 1991 872
248. Prandoni P. Fixed dose LMW heparin (CY216) as compared with adjusted dose intravenous heparin in the initial treatment of symptomatic proximal venous thrombosis [abstract] Thromb Haemost 65 suppl 1991 872
249. Hirsh J Levine MN. Low molecular weight heparin Blood 79 1992 1 17
250. Turpie AGG Levine MN Hirsh J A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery N Engl J Med 315 1986 925 929
251. Leclerc JR Geerts WH Desjardins L Prevention of deep vein thrombosis after major knee surgery: a randomized double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo Thromb Haemost 67 1992 417 423
252. Hoek JA Nurmohamed MT Hamelynck KJ Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid Thromb Haemost 67 1992 28 32
253. Planes A Vochelle N Mazas F Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement Thromb Haemost 60 1988 407 410
254. Eriksson BI Kalebo P Anthmyr BA Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement J Bone Joint Surg 73A 1991 484 493
255. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg 1994; 76(A):1174-85
256. Leclerc JR Geerts WH Desjardins L Prevention of venous thromboembolism (VTE) after knee arthroplasty: a randomized double-blind trial, comparing enoxaparin to warfarin sodium [abstract] Chest 106 suppl 1994 48 S
257. Bergqvist D Kettunen K Fredin H Thromboprophylaxis in hip fracture patients: a prospective randomized comparative study between ORG 10172 and dextran Surgery 109 1991 617 622
258. Borris LC Hauch O Jorgensen LN Low-molecular-weight heparin (enoxaparin) vs dextran 70: the prevention of postoperative deep vein thrombosis after total hip replacement Arch Intern Med 151 1991 1621 1624
259. Davidson B. Personal communication, 1992.
260. Leyvraz PF Bachmann F Bohnet J Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid lomoparan and heparin-dihydroergotamine Br J Surg 79 1992 911 914
261. Turpie AGG Levine MN Hirsh J A double-blind randomized trial of ORG 10172 low molecular weight heparinoid in the prevention of deep vein thrombosis in thrombotic stroke Lancet 1 1987 523 526
262. Prins MH den Ottolander GJH Gelsema R Deep vein thrombosis prophylaxis with a low molecular weight heparin (Kabi 2165) in stroke patients [abstract] Thromb Haemost 58 suppl 1987 117
263. Dahan R Houlbert D Caulin C Prevention of deep vein thrombosis in elderly medical patients by a low molecular weight heparin: a randomized double-blind trial Haemostasis 16 1986 159 164
264. Green D Lee MY Lim AC Prevention of thromboembolism after spinal cord injury using low molecular weight heparin Ann Intern Med 113 1990 571 574
265. Turpie AGG Gent M Cote R. et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke Ann Intern Med 117 1992 353 357
266. Ginsberg JS Hirsh J Turner DC Risk to the fetus of anticoagulant therapy during pregnancy Thromb Haemost 61 1989 197 203
267. Forestier F Daffos F Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound Thromb Res 34 1984 557 560
268. Forestier F Daffos F Rainaut M Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy Thromb Haemost 57 1987 234
269. Omri A Delaloye JF Andersen H Low molecular weight heparin NOVO (LHN-1) does not cross the placenta during the second trimester of pregnancy Thromb Haemost 61 1989 55 56
270. Melissari E, Das S, Kanthou C, et al. The use of LMW heparin in treating thromboembolism during pregnancy and prevention
271. Estoppey D Hochreiter J Breyer HG ORG 10172 (Lomoparin) versus heparin-DHE in prevention of thromboembolism in total hip replacement: a multicentre trial [abstract] Thromb Haemost 62 suppl 1989 356